Eli Lilly and Company
Dopamine D1 receptor positive allosteric modulators

Last updated:

Abstract:

The invention provides certain (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat certain symptoms of Parkinson's disease, schizophrenia, ADHD or Alzheimer's disease. ##STR00001##

Status:
Grant
Type:

Utility

Filling date:

17 Apr 2019

Issue date:

7 Apr 2020